Habif et al., 1995 - Google Patents

Regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma

Habif et al., 1995

Document ID
17152942768862204483
Author
Habif D
Ozzello L
De Rosa C
Cantell K
Lattes R
Publication year
Publication venue
Cancer investigation

External Links

Snippet

Two groups of patients with disseminated breast carcinomas who had failed radiotherapy, chemotheraphy, and hormonotherapy were treated with natural interferon a (nIFN-α) alone or in combination with nIFN-γ delivered in cycles of 10–12 intralesional (il) injections to …
Continue reading at www.tandfonline.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Similar Documents

Publication Publication Date Title
Tepper et al. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4
Bukowski Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin‐2
Aderka et al. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice.
Takatsuki et al. Interleukin 6 perfusion stimulates reconstitution of the immune and hematopoietic systems after 5-fluorouracil treatment
Fischer et al. Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates
Morrissey et al. The influence of IL-1 treatment on the reconstitution of the hemopoietic and immune systems after sublethal radiation.
Fu et al. The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF.
Garnick et al. Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma
AU640954B2 (en) Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or H2-receptor agonists
Barnes et al. Two cases of aplastic anaemia associated with tumours of the thymus
EP1803464A1 (en) External preparation for treating skin ulcer
Takeda et al. Murine tumor cells metastasizing selectively in the liver: ability to produce hepatocyte‐activating cytokines interleukin‐1 and/or‐6
Benjamin et al. Regulation of hemopoiesis in myelosuppressed mice by human recombinant IL-1 alpha.
Habif et al. Regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma
Miller et al. Randomized trial of recombinant α2b-interferon with or without indomethacin in patients with metastatic malignant melanoma
Lee et al. Bone modulation in sustained hematopoietic stimulation in mice
JP2008540553A (en) Method for modulating HLA class II tumor cell surface expression by cytokine mixtures
DE69130679T2 (en) THE PRODUCTION OF COMPOSITIONS FOR THE TREATMENT OF DISEASES OF CELL PROLIFERATION
Tomazic et al. Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro.
Takeuchi et al. Lung cancer producing interleukin-6
Thomsen et al. Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production
Hacham et al. Complementary organ expression of IL-1 vs. IL-6 and CSF-1 activities in normal and LPS-injected mice
Chen et al. Leukemoid reaction resulting from multiple cytokine production in metastatic mucoepidermoid carcinoma with central necrosis
Durie et al. Antitumor activity of bovine cartilage extract (Catrix-S) in the human tumor stem cell assay
Richard et al. Cytokines involved in the augmentation of murine natural killer cell activity by pyrimidinones in vivo